sc002 and Glioma

sc002 has been researched along with Glioma* in 1 studies

Other Studies

1 other study(ies) available for sc002 and Glioma

Article	Year
Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-15, Volume: 25, Issue:4 Isocitrate dehydrogenase (. We evaluated. Compared to. DLL3 is selectively and homogeneously expressed in Topics: Antibodies, Monoclonal, Humanized; Benzodiazepinones; Brain; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genotype; Glioma; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Isocitrate Dehydrogenase; Ligands; Male; Membrane Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Receptors, Notch; RNA	2019

Article

Year

Cell Surface Notch Ligand DLL3 is a Therapeutic Target in Isocitrate Dehydrogenase-mutant Glioma.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-15, Volume: 25, Issue:4

Isocitrate dehydrogenase (. We evaluated. Compared to. DLL3 is selectively and homogeneously expressed in

Topics: Antibodies, Monoclonal, Humanized; Benzodiazepinones; Brain; DNA Methylation; Female; Gene Expression Regulation, Neoplastic; Genotype; Glioma; Humans; Immunoconjugates; Intracellular Signaling Peptides and Proteins; Isocitrate Dehydrogenase; Ligands; Male; Membrane Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Recurrence, Local; Receptors, Notch; RNA

2019